Capricor Therapeutics, Inc.
CAPRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeCapricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD). Valued at $344.8M, CAPR is a small-cap name in its sector. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
Market Cap
$344.8M
Beta
0.61
P/E (TTM)
—
P/E (Fwd)
-4.09
EPS (TTM)
$-2.45
EPS (Fwd)
$-1.45
ROE
-73.7%
ROA
-33.6%
Cash
$237.9M
Total Debt
$91.0M
Free CF
-$89.2M
52W Change
-4.0%
Annual Financials
Cash vs Debt
Where CAPR stands vs its 150-day and 200-day moving averages
As of the October 8, 2026 close, CAPR finished 62.03% below its 150-day moving average ($21.33) and 63.87% below its 200-day moving average ($22.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CAPR overbought or oversold?
At the October 8, 2026 close, CAPR's RSI(14) was 37.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $237.9M in cash comfortably exceeding the $91.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$89.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -73.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $2.6M (2022) to $0 (2025), a 100% decline worth watching.
The relatively low beta of 0.61 suggests CAPR is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CAPR's risk profile alongside its fundamentals and technical indicators provides a more complete picture.